Icon Group partners with SeeTreat to pioneer precision radiation therapy
Icon Group (Icon), will be the first to partner with SeeTreat to lead innovation in precision radiation therapy treatment.
SeeTreat is a unique Australian medical software start-up who is solving real clinical problems in radiotherapy through software solutions that are high quality, efficient and patient and user centric.
This collaboration will see Icon trial SeeTreat's software innovation, ART.1, at select cancer centres in Australia. ART.1 accurately measures a patient's radiotherapy dose daily to ensure patients receive the right treatment at the right time for their anatomy, which can change during treatment and over time.
In line with Icon's commitment to exceptional patient care and innovation, Icon will be testing and validating ART.1 software at two Queensland locations - Icon Cancer Centre Toowoomba and Icon Cancer Centre Greenslopes. During the trial period, Icon and SeeTreat will work together to make the product suitable for widespread use once commercially released in early 2024.
SeeTreat CEO and Founder, Dr Trang Nguyen said Icon's commitment to improving access to world-class cancer care aligns with SeeTreat's vision and goals.
“Working with Icon has been an absolute pleasure, with both organisations clearly aligned and working toward the same goal of improving patient care. Professor Paul Keall and I founded SeeTreat to “turn the light on for cancer treatment”, enabling the treatment team to see what we treat, and know whether the radiation is deposited as planned such that clinicians can course-correct as needed.”
Icon Group Executive Manager of Clinical Care, Trent Aland said this partnership reflects Icon's ongoing commitment to investing in the latest technologies.
“We're excited to be working with a "home grown" Australian innovator who is breaking new ground in radiotherapy innovation and developing software with a focus on improving workflow for clinical teams and most importantly quality of care.
We're looking forward to trialing this software and hopefully adding it to Icon's leading fleet of radiotherapy technology and improving access to the latest in cancer care across Australia.”
— Icon Group Executive Manager of Clinical Care, Trent Aland
This collaboration is the latest in Icon's investment in strong industry partnerships designed to improve cancer care technology and deliver better patient care and outcomes.
SeeTreat and Icon will work closely throughout the trial and validation period to determine suitability and efficacy of the product before it is released widely.
Related news
Dr Trang Nguyen29 September 2026C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic
C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic UPPSALA, Sweden/SYDNEY, Australia – September 29, 2026 – C-RAD (publ) the global leader in surface-guided radiation therapy (SGRT), and SeeTreat Pty Ltd, a pioneer in the adaptive decision support radiotherapy (ART) software, today confirm a partnership to co-develop more connected, intelligent, and patient-centric radiotherapy workflows.
Read more
Dr Sean Pollock17 September 2026ABC Radio National interview - Changing Australia: Paul Keall and innovating with radiotherapy
SeeTreat co-founder Professor Paul Keall speaks with Sally Sara on innovating with radiotherapy. Prof Keall writes of this interview: "It was an honour to be invited to contribute to the ABC's Changing Australia series hosted by Sally Sara. On the question of how to bring innovations in radiotherapy to large numbers of patients I am proud that we at SeeTreat are doing just that: developing accessible technology to ensure that the radiation treatment is personalised to the patient throughout their course of therapy."
Read more
Antonia Dalton19 May 2026SeeTreat's ART.1-US Software is FDA Cleared for clinical use in the USA
SYDNEY, May 18, 2026 /PRNewswire/ -- SeeTreat's ART.1-US software delivering automated adaptive decision support for every patient at every treatment is cleared for use in the USA. From today, US clinics with Varian or Elekta CT linear accelerators, will be able to access daily evaluations of radiotherapy dose to patients' changing anatomy. With ART.1-US, clinical teams can now decide the right time for a new radiotherapy plan in 95+ seconds[1], and download supporting clinical documentation.
Read more